Eric Joseph Daniels - Mar 3, 2023 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Role: Chief Development Officer
Signature: /s/ Robert A. Petitt, Attorney-in-Fact
Stock symbol: KPRX
Transactions as of: Mar 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/7/2023, 07:14 PM
Previous filing: Oct 25, 2022
Next filing: Oct 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPRX	Common Stock	Award	$0	+15.6K	+152.37%	$0.00	25.8K	Mar 3, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPRX	Stock Option (right to buy)	Award	$0	+10.4K		$0.00	10.4K	Mar 3, 2023	Common Stock	10.4K	$3.83	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of March 3, 2024, March 3, 2025 and March 3, 2026, subject to the reporting person's continuous service through each such vesting date.
F2	The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 3, 2024, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Content

Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of March 3, 2024, March 3, 2025 and March 3, 2026, subject to the reporting person's continuous service through each such vesting date.

The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 3, 2024, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.